Form 4: Moderna Director David Rubenstein Receives Equity Grant

Moderna Director David Rubenstein was granted stock options and restricted stock units as part of his annual compensation.

Summary

• Director David M. Rubenstein received a grant of 9,681 stock options with an exercise price of $48.79.
• Director David M. Rubenstein received a grant of 2,092 restricted stock units (RSUs).
• Both the stock options and RSUs are scheduled to vest on the earlier of May 6, 2027, or the date of Moderna's next Annual Meeting of Shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company strategy or financial health.

Positives

• Equity-based compensation aligns the interests of the director with those of long-term shareholders.

Negatives

• The issuance of new equity awards results in minor dilution to existing shareholders.

Risks

• Vesting is subject to the recipient's continued service to the company.

Future Outlook

The equity grants are standard compensation for board service and do not indicate specific forward-looking operational guidance.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The grant structure is consistent with standard annual compensation packages for independent directors at large-cap pharmaceutical and biotech firms.
• Vesting periods of one year are typical for annual director equity awards in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity awards on May 6, 2027, or the next Annual Meeting of Shareholders.

Key Dates

Keywords

Moderna, MRNA, Director Compensation, Equity Grant, Insider Transaction, Form 4